| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |